Mary Ann Gray
CIK 1261974 · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACAD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10023
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Director | 12,392 | $11.56 | $143.3K | $0 | 7 | 2026-06-05 |
| RAPT Therapeutics, Inc. (RAPT) Delisted | Director | 4,956 | $58.01 | $287.5K | $0 | 14 | 2026-02-02 |
| CMPX | Director | — | $0.76 | — | $0 | 5 | 2026-01-05 |
| BioAtla, Inc. (BCAB) Delisted | Director | 1,548 | $1.74 | $2.7K | $0 | 9 | 2025-06-18 |
| PALI | Director | — | $1.21 | — | $0 | 3 | 2023-11-24 |
| SRPT | Director | 12,356 | $18.55 | $229.2K | $0 | 8 | 2022-03-08 |
| PALISADE BIO, INC. (SNCA) Delisted | Director | — | $9.96 | — | $0 | 2 | 2021-04-26 |
| SENOMYX INC (SNMX) Delisted | Director | 0 | — | — | $10.0K | 10 | 2018-11-02 |
| JUNIPER PHARMACEUTICALS INC (JNP) Delisted | Director | 0 | — | — | $0 | 4 | 2018-08-15 |
| SELLAS Life Sciences Group, Inc. (GALE) Delisted | Director | 1,306 | — | — | $0 | 6 | 2017-10-10 |
| ACAD | Director | 139,476 | $20.24 | $2.82M | -$847.8K | 13 | 2016-06-09 |
| DYAX CORP (DYAX) Delisted | Director | 0 | — | — | $0 | 5 | 2016-01-22 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | Director | — | — | — | $0 | 2 | 2015-01-30 |
| GTC BIOTHERAPEUTICS INC (GTCB) Delisted | Director | 1,100 | — | — | $8.8K | 3 | 2008-06-25 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (TELK) Delisted | Director | — | — | — | $0 | 2 | 2008-05-22 |
Recent Filings · Page 8 of 10
94 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-05-14 | DYAX CORP (DYAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-01-30 | TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-01-15 | ACAD | Mixed | — | -$102.0K | EDGAR |
| 2014-12-17 | ACAD | Mixed | — | -$273.0K | EDGAR |
| 2014-11-07 | TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-08-28 | ACAD | Mixed | — | -$187.0K | EDGAR |
| 2013-06-14 | SENOMYX INC (SNMX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-06-11 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2012-06-22 | DYAX CORP (DYAX) Delisted | Mixed | — | $0 | EDGAR |
| 2012-06-11 | ACAD | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.